Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients

2016 ◽  
Vol 14 (2) ◽  
pp. 158-164 ◽  
Author(s):  
Christoffer Gebhardt ◽  
Ramtin Lichtenberger ◽  
Jochen Utikal
Keyword(s):  
High Risk ◽  
Serum S100b ◽  
High Risk Melanoma ◽  
Risk Melanoma ◽  
Melanoma Patients

Evaluation of IL-10 polymorphisms in high-risk melanoma patients receiving adjuvant interferon

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 9049-9049
Author(s):  
H. Gogas ◽  
Y. Metaxas ◽  
A. Polyzos ◽  
M. Mantzourani ◽  
A. Antoniadis ◽  
...  
Keyword(s):  
High Risk ◽  
Interleukin 10 ◽  
High Risk Group ◽  
High Dose ◽  
Healthy Controls ◽  
Nucleotide Polymorphisms ◽  
High Risk Melanoma ◽  
Risk Melanoma ◽  
Melanoma Patients

9049 Background: Attempts to identify patients who benefit from adjuvant treatment of interferon alfa-2b (IFN) have been disappointing. Interleukin-10 polymorphisms have been implicated with the prognosis of patients with advanced melanoma and associated with response to biochemotherapy. Several polymorphisms have been found within the IL-10 gene. We evaluated three IL-10 Single Nucleotide Polymorphisms (SNPs) in high-risk melanoma patients enrolled in a study of two regimens of high-dose IFN and compared the distribution of SNPs found in healthy controls. Methods: We genotyped DNA from peripheral blood of 280 stage IIb, IIc and III melanoma patients and 288 healthy controls for 592 C/A, 819 C/T and 1082 G/A with PCR and pyrosequencing technology (Biotage, Uppsala, Sweden). Results: At a median follow up of 56.3 months (95% CI 47.4–63.7), 147 patients have recurred and 94 have died. The median DFS was 53 months and the median OS 86 months. There were no statistically significant differences in the incidence of IL-10 polymorphisms between the melanoma patients and healthy controls. The incidence of these polymorphisms is presented in table . RFS and OS did not differ significantly between the alleles of these polymorphisms (p=0.88 and p=0.55 for 592 C/A, p=0.84 and p=0.68 for 819 C/T and p=0.26 and p=0.30 for 1082 G/A respectively). Conclusions: No SNP studied was correlated with improved RFS and OS in this high-risk group of melanoma patients. [Table: see text] [Table: see text]

The Role of Surveillance Chest X-Rays in the Follow-Up of High-Risk Melanoma Patients

2008 ◽  
Vol 16 (3) ◽  
pp. 571-577 ◽  
Author(s):  
Rachael L. Morton ◽  
Jonathan C. Craig ◽  
John F. Thompson
Keyword(s):  
High Risk ◽  
X Rays ◽  
High Risk Melanoma ◽  
Risk Melanoma ◽  
Melanoma Patients

scholarly journals CN4 COST-EFFECTIVENESS (CE) ANALYSIS OF INTERFERON-ALPHA IN HIGH-RISK MELANOMA PATIENTS

2004 ◽  
Vol 7 (3) ◽  
pp. 221 ◽  
Author(s):  
M Ding ◽  
Y Xing ◽  
T Shih ◽  
D Cox ◽  
S Cantor ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
High Risk ◽  
Interferon Alpha ◽  
High Risk Melanoma ◽  
Risk Melanoma ◽  
Melanoma Patients

A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients

2017 ◽  
Vol 67 (2) ◽  
pp. 285-298 ◽  
Author(s):  
Olivier Gasser ◽  
Katrina J. Sharples ◽  
Catherine Barrow ◽  
Geoffrey M. Williams ◽  
Evelyn Bauer ◽  
...  
Keyword(s):  
T Cells ◽  
Dendritic Cells ◽  
High Risk ◽  
Phase I ◽  
High Risk Melanoma ◽  
Risk Melanoma ◽  
Melanoma Patients ◽  
Polyfunctional T Cells

Neoadjuvant Systemic Therapy for High-Risk Melanoma Patients

2020 ◽  
pp. 767-793
Author(s):  
Emily Z. Keung ◽  
Rodabe N. Amaria ◽  
Vernon K. Sondak ◽  
Merrick I. Ross ◽  
John M. Kirkwood ◽  
...  
Keyword(s):  
High Risk ◽  
Systemic Therapy ◽  
High Risk Melanoma ◽  
Risk Melanoma ◽  
Neoadjuvant Systemic Therapy ◽  
Melanoma Patients
Sign in / Sign up

Export Citation Format

Share Document